246P - The association of plasma soluble major histocompatibility complex class I polypeptide-related sequence A (sMICA) level with the pathological compl...

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Oesophageal Cancer
Pathology/Molecular Biology
Translational Research
Presenter Hung-Yang Kuo
Citation Annals of Oncology (2016) 27 (suppl_9): ix68-ix85. 10.1093/annonc/mdw582
Authors H. Kuo1, Y. Lin2, J. Guo3, T. Huang3, C. Lin3, K. Yeh3, A. Cheng3, C. Hsu3, C. Chang2
  • 1Oncology Division/department Of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, 300 - Hsinchu City/TW
  • 2Institute Of Molecular And Cellular Biology And Department Of Life Science, National Tsing Hua University, 30013 - Hsinchu City/TW
  • 3Oncology Department, National Taiwan University Hospital, 10048 - Taipei/TW

Abstract

Background

MICA is a ligand for the NKG2D receptors expressed on NK cells and certain types of T cells. Under various types of stress, MICA is induced and shed from the cell surface into the circulation generating a soluble form (sMICA). The sMICA level has been reported to be associated with disease progression of several malignancies and its significance in ESCC patients is unknown.

Methods

Thirty-one patients with locally advanced ESCC (all AJCC 6th ed. T3N0-1M0-1a) who had undergone neoadjuvant paclitaxel/cisplatin-based chemoradiotherapy (CRT) followed by esophagectomy in a prospective phase II clinical trial (Lin CC et al: J Clin Oncol 2013;31; suppl; abstr 4099) were included. Their plasma sMICA levels were measured by quantitative ELISA before CRT, after CRT, and after surgery, and then correlated with pCR rate and survival outcomes.

Results

With a median follow-up of 51.0 months, the median recurrence-free survival (RFS) and overall survival (OS) of these patients was 23.7(95%C.I. 25.1-48.1) and 51.0 (95%C.I. 39.9-61.1) months. The median (range) of baseline, post-CRT and post-surgery sMICA level was 66.5 (26.1-457.5), 65.0 (25.2-534.6) and 66.9 (25.4-377.3) pg/ml. Patients with low baseline sMICA, defined as less than the median level, had significantly higher pCR rate than those with high baseline sMICA [62.5% (10/16) vs. 20% (3/15), p = 0.017]. The median RFS (33.9 vs. 22.9m, p = 0.811) and OS (51.0 vs. 51.0m, p = 0.827) were not significantly different between patients with low and high baseline sMICA levels.rn

Table: 246P

rnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrn
Baseline plasma sMICA level and pCR rate (n = 31)
Baseline plasma sMICApCR rateMedian RFS(m)Median OS(m)
All41.9% (13/31)23.751.0
High20.0% (3/15)22.951.0
Low62.5% (10/16)33.951.0

Conclusions

In this relatively small cohort, the low plasma sMICA level was associated with an increased pCR rate in locally advanced ESCC treated with neoadjuvant CRT. Further confirmatory studies with a larger patient population are warranted. (The work was supported by the Grant of HCH105-021 and MOST 104-2320-B-007-002)

Clinical trial indentification

none

Legal entity responsible for the study

National Taiwan University Hospital and Hsin-Chu Branch, National Tsing Hua University

Funding

National Taiwan University Hospital Hsin-Chu Branch, Ministry of Science and Technology

Disclosure

All authors have declared no conflicts of interest.